Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Keros Therapeutics (KROS) Receivables Refunds (2025)

Keros Therapeutics filings provide 1 years of Receivables Refunds readings, the most recent being $2.2 million for Q4 2025.

  • On a quarterly basis, Receivables Refunds changed N/A to $2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 million, a N/A change, with the full-year FY2025 number at $2.2 million, changed N/A from a year prior.
  • Receivables Refunds hit $2.2 million in Q4 2025 for Keros Therapeutics.
  • In the past five years, Receivables Refunds ranged from a high of $2.2 million in Q4 2025 to a low of $2.2 million in Q4 2025.